New data further confirm Wegovy cuts risk of heart attacks

11 November 2023

New data were presented today at the American Heart Association (AHA) annual Scientific Sessions in Philadelphia on SELECT, Novo Nordisk’s (NOV: N) landmark Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg (trade name Wegovy) in adults with established cardiovascular disease (CVD) and overweight or obesity

The data were simultaneously published in the New England Journal of Medicine (NEJM).

Previously reported top-line results showed semaglutide 2.4mg delivered a statistically-significant 20% risk reduction in major adverse cardiovascular events (MACE over a period of up to five years versus placebo (HR: 0.80; 95% confidence interval: 0.72; 0.90, p<0.001).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK